The FDA has granted Breakthrough Therapy designation to apabetalone in combination with standard of care therapy for the secondary prevention of MACE in patients with T2Dm and recent ACS.
All articles by Brian Park, PharmD
-
Latest News Your top articles for Thursday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses